SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai has announced the launch of Viz RECRUIT, cutting edge software that uses artificial intelligence to accelerate clinical studies. Viz RECRUIT uses AI to automatically detect a suspected disease such as a brain hemorrhage, a tumor, or a cardiac structural abnormality, and uses that insight to ensure the right doctor is notified about the patient. This improves workflow and expedites enrollment in trials. Viz RECRUIT alerts research teams about potentially eligible trial patients across an entire health system and enables easy communication between clinical teams, research teams, principal investigators, and core labs to facilitate enrollment.
Clinical trials are used to approve new procedures, devices, and drugs as standards of care. These studies can take years and upwards of millions of dollars to complete as research teams are challenged to first identify, then enroll patients meeting specific enrollment criteria. Viz.ai developed Viz RECRUIT to address these challenges. The first industry sponsored clinical study to use Viz RECRUIT is the ENRICH trial, sponsored by NICO Corp., investigating minimally invasive hematoma extraction for intracranial hemorrhage patients. One site, University of Buffalo, that now uses Viz RECRUIT enrolled at 3.3 times the rate than without Viz RECRUIT, and was described by investigators like Dr. Adnan Siddiqui as the “future of clinical trials.”
Jim Pearson, CEO of Nico Corp., said, “The initial ENRICH sites that have enabled Viz RECRUIT are picking up enrollment velocity. There is immense value to both the patient and industry in potentially completing trials in less time and with better efficiency. We are excited to see Viz RECRUIT continue to grow in its market utilization.”
Dr. Brian Jankowitz, Neurosurgeon and Director of Cerebrovascular Program at Cooper University Health Care, and an ENRICH investigator, added, “Viz RECRUIT is how clinical trials should be run. We are able to be alerted to potential patients and quickly move them to enrollment and treatment. I hope we can use Viz RECRUIT for all of our other clinical studies.”
Viz RECRUIT is becoming the standard for neurovascular clinical trials, and there are several new additional clinical trials that will begin enrolling later this year.
About Viz.ai, Inc.
Viz.ai is the leader in applied artificial intelligence in healthcare. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of diffusion of medical innovation. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis. A third FDA clearance was granted in 2020 for Viz ICH, which uses AI to automatically detect suspected intracranial hemorrhage on CT imaging. In 2020, CMS granted Viz.ai the first New Technology Add-on Payment (NTAP) for artificial intelligence software for Viz LVO.
Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Greenoaks, CRV, and Threshold.
